# Larimar Therapeutics, Inc. Common Stock (LRMR)

> Larimar Therapeutics, Inc. Common Stock (LRMR) trades at $2.39 (+3.02%) as of 7:57:45 PM EST on Nov 6, 2026, -11.48% over the past month. Market cap is $248.28M, with 8.9 days to cover in short interest.

Canonical: https://massive.com/quote/lrmr
Data as of: 2026-11-07T00:57:45.904Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.39** +0.07 (+3.02%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$2.43** +0.04 (+1.67%)
As of 7:57:45 PM EST on Nov 6, 2026 · After hours

## Stock performance

How Larimar Therapeutics, Inc. Common Stock (LRMR) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +3.02% |
| 1W | -3.24% |
| 1M | -11.48% |
| YTD | -37.27% |
| 1Y | -32.68% |
| 52-wk range | $1.92 – $6.42 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for LRMR: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.30 – $2.48 |
| Open | $2.36 |
| Prev close | $2.32 |
| Volume | 973.64K |
| Market cap | $248.28M |
| Shares out | 103.88M |

## Valuation and profitability ratios

Valuation and profitability ratios for Larimar Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.95 |
| P/FCF | — |
| ROE | -135.5% |
| ROA | -104.4% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 6, 2026

## Insider trading

[Larimar Therapeutics, Inc. Common Stock (LRMR) insider trading](https://massive.com/quote/lrmr/insider-trading.md): open-market Form 4 buys and sells by Larimar Therapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Larimar Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Sep 29, 2026 · Executive compensation change
  “The Employment Agreement provides for an initial base salary of $560,000 per annum, which is subject to annual review and adjustment by the Compensation Committee of the Board (the "Compensation Committee"). In addition, Mr. Harlow will receive a cash signing bonus of $35,000 and is eligible to earn an annual bonus with a target amount equal to 40% of his annual base salary.”
- Aug 4, 2026 · Investor presentation
  “On August 4, 2026, the Company posted on its website an updated slide presentation... Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.”
- Jun 29, 2026 · Investor presentation
  “the Company will host a conference call to discuss a regulatory update and use a slide presentation in conjunction with the call. A copy of the presentation is filed herewith as Exhibit 99.2”
- May 19, 2026 · Charter amendment
  “The stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's Common Stock from 115,000,000 to 215,000,000.”
- May 14, 2026 · Investor presentation
  “On May 14, 2026, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.”

## LRMR short interest

How heavily LRMR is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.9 |
| Short interest | 14.66M |
| Avg volume | 1.64M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## LRMR news

The latest news and headlines about Larimar Therapeutics, Inc. Common Stock (LRMR).

- [Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner](https://www.zacks.com/stock/news/3000042/larimar-lrmr-loses-22-7-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-ZC-FT-fundamental_analysis|rsi-3000042) · Zacks Investment Research · Oct 5, 2026 · positive sentiment
- [INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR](https://www.globenewswire.com/news-release/2026/07/07/3323750/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Larimar-Therapeutics-Inc-LRMR.html) · GlobeNewswire Inc. · Jul 7, 2026 · negative sentiment
- [Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering](https://www.benzinga.com/pressreleases/26/02/g50875986/larimar-therapeutics-announces-pricing-of-upsized-100-million-underwritten-public-offering?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Feb 25, 2026 · positive sentiment
- [Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering](https://www.globenewswire.com/news-release/2026/02/26/3245161/0/en/Larimar-Therapeutics-Announces-Pricing-of-Upsized-100-Million-Underwritten-Public-Offering.html) · GlobeNewswire Inc. · Feb 25, 2026 · positive sentiment
- [Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR](https://www.benzinga.com/pressreleases/25/10/n48243837/larimar-therapeutics-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to) · Benzinga · Oct 16, 2025 · negative sentiment

## About Larimar Therapeutics, Inc. Common Stock

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 71 |
| Listed | May 29, 2020 |

[Company website](https://www.larimartx.com)

## FAQ

### What is the Larimar Therapeutics, Inc. Common Stock (LRMR) stock price today?

Larimar Therapeutics, Inc. Common Stock (LRMR) is trading at $2.39 (+3.02% on the day) as of 7:57:45 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Larimar Therapeutics, Inc. Common Stock?

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform.

### What is the short interest in LRMR?

As of Oct 15, 2026, LRMR has 14.66M shares short and 8.9 days to cover.

### What exchange is LRMR listed on?

Larimar Therapeutics, Inc. Common Stock (LRMR) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time LRMR quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=LRMR`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Larimar Therapeutics, Inc. Common Stock (LRMR) insider trading](https://massive.com/quote/lrmr/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms